ALX raises $105M for midphase trials of CD47 cancer drug

ALX raises $105M for midphase trials of CD47 cancer drug

Source: 
Fierce Biotech
snippet: 

ALX Oncology has raised $105 million. The series C round will support phase 2 trials of CD47 myeloid checkpoint inhibitor ALX148 in combination with other anti-cancer therapies.